CHARLES KUNSCH

Charles Kunsch is a distinguished Managing Director at AbbVie Ventures, the corporate venture capital arm of the global biopharmaceutical company AbbVie. In this influential role, he is instrumental in sourcing, evaluating, and investing in innovative early-stage biotechnology, pharmaceutical, and medical device companies. His work directly contributes to AbbVie's mission of discovering and delivering transformative medicines by identifying promising technologies and platforms that complement the parent company's strategic therapeutic areas.

Kunsch's investment focus is broad yet targeted, primarily concentrating on areas of high unmet medical need. These include oncology, where he seeks novel approaches to cancer treatment; immunology, exploring new therapies for autoimmune and inflammatory diseases; and neuroscience, investigating solutions for neurological and psychiatric disorders. He also has interests in other emerging fields that align with AbbVie's long-term vision, such as virology, women's health, and eye care. His expertise allows him to critically assess scientific merit, clinical potential, and market opportunity, guiding AbbVie Ventures' strategic investments.

Before joining AbbVie Ventures, Charles Kunsch built a robust career marked by significant contributions across various facets of the biopharmaceutical industry. He holds a Ph.D. in Molecular Biology, providing him with a profound understanding of the scientific underpinnings of drug discovery and development. His professional journey includes extensive experience in research and development, as well as business development roles at leading pharmaceutical companies, including Abbott Laboratories prior to the spin-off of AbbVie. This diverse background has equipped him with a unique perspective that bridges cutting-edge science with strategic business acumen, making him a valuable asset in the venture capital landscape.

While specific individual investments are often part of a broader fund strategy, Charles Kunsch's involvement typically extends to companies developing novel therapeutic modalities, precision medicines, and disruptive technologies aimed at improving patient outcomes. He actively supports portfolio companies through strategic guidance, leveraging AbbVie's extensive resources and expertise to help them achieve their scientific and commercial milestones. His commitment to fostering innovation underscores his dedication to advancing healthcare and bringing life-changing treatments to patients worldwide.